Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIMAvax in Combination With Anti-PD1 Therapy in Advanced NSCLC or Squamous Head and Neck Cancer
NCT02955290Phase 2Active, not recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Dec 2016
- Primary completion
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of cimavax egf in non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (HNSCC) (4 arms), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Dose Limiting Toxicity at 4 weeks, Overall Survival at 12 months and 1 more. Started Dec 2016; status: active, not recruiting.
02
Drugs
cimavax egf
03
Conditions
non-small cell lung cancer (NSCLC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02955290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955290.